Overview

Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the tolerability and safety of SAD448 and explore the compound's effect on intraocular pressure in subjects with ocular hypertension.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis